Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia.
暂无分享，去创建一个
R. Ulrich | J. Byrd | I. Flinn | J. Brown | D. Benson | L. Miller | S. Coutre | R. Furman | N. Wagner-Johnston | S. Spurgeon | B. Kahl | B. Lannutti | H. Hsu | A. Yu | L. Holes | S. Peterman | Leanne Holes | John C. Byrd | Jennifer R. Brown | Brad S. Kahl | Langdon L. Miller